Table 3: Clinical and pathological response according to the molecular subtype of the patients included in the study.
|
Subtype |
Pathological response (Chevallier criteria) (n = 51) |
Subtype |
Clinical response (WHO criteria) (n = 56) |
||||||
|
Class 1 |
Class 2 |
Class 3 |
Class 4 |
Complete response |
Partial response |
Stable disease |
Progression |
||
|
Luminal A (n = 44, 86.3%) |
1 (2.3) |
0 |
29 (65.9) |
14 (31.8) |
Luminal A (n = 48, 86%) |
5 (10.4) |
8 (16.7) |
33 (68.7) |
2 (4.2) |
|
Luminal B (n = 7, 13.7%) |
0 |
0 |
4 (57.1) |
3 (42.9) |
Luminal B (n = 8, 14.0%) |
1 (12.5) |
0 |
6 (75) |
1 (12.5) |
|
Total (n = 51, 100%) |
1 (2.0) |
0 |
33(64.7) |
17(33.3) |
Total (n = 56, 100%) |
6 (10.7) |
8 (14.3) |
39 (69.6) |
3 (5.4) |